Desmopressin (DDAVP)
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Desmopressin (DDAVP) is listed as renal / avp analog.
- •Diabetes Insipidus
- •vWD Type I
- •Nocturia
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Desmopressin (DDAVP); also known as DDAVP, Stimate, Nocdurna.
Pharmacologic class: Renal / AVP Analog.
Known delivery routes: Oral, Intranasal, Intravenous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
V2 receptor agonist — increases renal water reabsorption via AQP2 upregulation; promotes vWF and Factor VIII release.
- •Controls polyuria in central DI
- •Reduces nocturia frequency
- •Hemostasis in mild vWD/hemophilia A
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Multiple Phase III trials.
Laboratory Research
Multiple Phase III trials
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Bedtime for nocturnal enuresis / nocturia. Restrict fluids 1 hr before to 8 hrs after.
Potential interactions and combinations to avoid
- •Concurrent thiazides, SSRIs, NSAIDs — hyponatremia risk
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Hyponatremia (potentially fatal)
- •Seizures in children
- •Headache
- •Fluid retention
Contraindications
- •Hyponatremia history
- •Moderate–severe renal impairment
- •SIADH
- •Heart failure with fluid overload
- •Hyponatremia, SIADH, or excessive free-water intake
- •Coronary artery disease, peripheral vascular disease, or Raynaud phenomenon
- •Uncontrolled hypertension or arrhythmia
- •Severe heart failure or volume overload
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.1–0.4 mg/day (oral); 10–40 mcg/day (intranasal)
Frequency: Daily to BID
Cycling: Continuous; fluid restriction required.
Oral
Nocturia / enuresis.
Tablet or sublingual ODT. 1 hour before bed. Fluid-restrict 1 h before to 8 h after.
Intranasal
Diabetes insipidus, some coagulation uses.
Metered nasal spray. 1 spray per nostril at bedtime; alternate nostrils.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Fluid-restriction protocol
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
At bedtime for nocturnal enuresis; morning for daytime indications.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Intranasal — Alternate nostrils, spray on inhalation, do not sniff hard.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous; fluid restriction required.
Timing & Interactions
- ·Concurrent thiazides, SSRIs, NSAIDs — hyponatremia risk
- ·Fluid-restriction protocol
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Desmopressin (DDAVP) and sync them to Vial Lab.
Benefits
- ·Controls polyuria in central DI
- ·Reduces nocturia frequency
- ·Hemostasis in mild vWD/hemophilia A
Risks
- ·Hyponatremia (potentially fatal)
- ·Seizures in children
- ·Headache
- ·Fluid retention
Contraindications
- ·Hyponatremia history
- ·Moderate–severe renal impairment
- ·SIADH
- ·Heart failure with fluid overload
- ·Hyponatremia, SIADH, or excessive free-water intake
- ·Coronary artery disease, peripheral vascular disease, or Raynaud phenomenon
- ·Uncontrolled hypertension or arrhythmia
- ·Severe heart failure or volume overload
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Desmopressin (DDAVP). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Cited Works
Tap any study to open the published work.